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and Richard P. Cambria, MD, Boston, Mass
Background: Although percutaneous intervention (PTA) is considered first-line therapy for peripheral vascular disease in
many scenarios, its role in critical limb ischemia (CLI), wherein anatomic disease is more extensive, remains unclear. In
the present study, late (5-year) clinical and patency data for PTA in CLI are defined.
Methods: From January 2002 to December 2007, 409 patients underwent infrainguinal PTA stent for CLI (Rutherford
IV-VI) of 447 limbs. Primary patency, assisted patency, limb salvage, and survival were assessed using Kaplan-Meier.
Predictors of patency, limb salvage, and death were determined using multivariate models.
Results: Demographics included age (70  12 years old), diabetes (65.8%), and dialysis dependence (13%). The
superficial femoral artery was treated in 58% of the patients, 16% were limited to the crural vessels, 38% had
multilevel treatment, and stents were placed in 26%. Eighty percent of patients received postprocedure clopidogrel.
Mean follow-up was 28 months (0-83). Five-year primary and assisted patency were 31%  0.04 and 75%  0.04,
respectively. Limb salvage at 5 years was 74%  0.038. Sixty-three patients had major amputations. Survival at 5
years was 39%  0.03. Multivariate analysis identified dialysis dependence (P  .0005; 2.7 [1.6-4.8]), <1 vessel
runoff (P  .02; 1.5 [1.1-2.0]), and warfarin use (P  .001; 1.7 [1.25-2.3]) as negative predictors of primary
patency, but none of these were negative predictors of assisted patency. Dialysis dependence (P  .006; 2.5
[1.3-4.8]), female gender (P  .02; 2.0 [1.1-3.7]), and <1 vessel run-off (P  .04; 1.8 [1.0-3.2]) predicted limb
loss. Dialysis dependence (P  .0003; 2.3 [1.5-3.5]), diabetes (P  .04; 1.5 [0.5-2.1]), and poor run-off (P  .04;
1.6 [1.2-2.1]) were predictors of mortality.
Conclusion: Although primary patency is low, excellent limb salvage rates can be achieved in patients with CLI through
close follow-up and secondary interventions. These data, and the 12% annual death rate, validate PTA as first-line therapy


























bFor patients with critical limb ischemia (CLI), surgical
bypass grafting (preferably with autologous vein) remains
the gold standard of revascularization, with 5-year limb
salvage rates exceeding 80% in patients presenting with a
nonhealing ulcer or rest pain.1,2 However, it is increasingly
rare to find a patient with CLI who has an adequate length
of usable great saphenous vein, and the use of less than
optimal “high-risk” conduit has been shown to produce
inferior amputation-free survival.3 Percutaneous translumi-
nal angioplasty with or without stenting (PTA/stent) of
infrainguinal arterial occlusive disease can be accomplished
with low perioperative morbidity. Mortality and acceptable
midterm-assisted patency and limb salvage rates have led
many to recommend PTA/stent as first-line therapy in
patients with chronic lower extremity ischemia.4-6
Despite similar low complication rates after an infrain-
guinal PTA/stent, primary patency rates inferior to surgical
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1020ypass have fueled the argument that this modality should
e reserved for patients who are at high surgical risk or lack
utogenous conduit.7,8 Indeed, a Delphi consensus study
erformed in England found that there was disagreement
egarding the appropriateness of treatment with angio-
lasty or bypass surgery in 81% of the scenarios of severe
imb ischemia shown to a panel of 20 consultant vascular
urgeons.9 There has been one multicenter, randomized trial
hat compared a PTA/stent to surgical bypass in patients with
LI (bypass vs angioplasty in severe ischemia of the leg) and it
howed no difference in the primary outcome of 6-month
mputation-free survival between the two treatment modali-
ies.6 In addition, several single-center series have shown
xcellent limb salvage rates with a PTA/stent, but these stud-
es are limited by postprocedure follow-up that averaged 10 to
4 months.4,7,10 The goal of this study was to evaluate the
ong-term outcomes of PTA/stent in a large single-center
opulation of patients with chronic CLI.
ETHODS
Patients. All patients with CLI (Rutherford classifica-
ion IV-VI)11 and native infrainguinal arterial occlusive
isease who were managed with a PTA/stent between
anuary 2002 and December 2007 were identified retro-
pectively. During the study interval, 409 patients under-
ent a PTA/stent for chronic CLI with 447 limbs treated.
he decision to use PTA/stent as first-line therapy was
ased on the clinical examination, anatomic evaluation, and
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Volume 53, Number 4 Conrad et al 1021presented with acute limb ischemia requiring emergent
revascularization or a functionally unsalvageable limb were
excluded from evaluation. In addition, patients who under-
went a PTA/stent of threatened bypass grafts (vein or
prosthetic) or received adjuvant therapies such as mechan-
ical thrombectomy, atherectomy, cryoplasty, or thrombol-
ysis, were not included in this cohort. Individual limbs were
counted separately so that patients undergoing staged,
bilateral procedures were recorded and evaluated as two
entries. The Institutional Review Board of the Massachu-
setts General Hospital approved the clinical protocol.
Demographic, preoperative, perioperative, and postop-
erative data, including lesion anatomy according to the
TransAtlantic Inter Society Consensus (TASC) I and II
femoropopliteal and tibial systems12,13 and follow-up
ankle-brachial indices (ABIs) and/or pulse volume record-
ings were collected for each patient. A history of renal
insufficiency was defined as a preprocedure creatinine1.5
mg/dL and patients were considered to have a history of
heart disease even if they had previously been revascularized
with coronary artery angioplasty or bypass grafting. A
multi-level intervention was defined as a femoropopliteal
intervention in conjunction with a tibial intervention. A
multi-vessel intervention was defined as a PTA/stent in
more than one named vessel.
PTA/stent procedure. All infrainguinal PTA/stents
were performed in our fixed-imaging operating room suite
or cardiac catheterization laboratory by interventionalists
who satisfied Society for Vascular Surgery criteria for per-
formance of endovascular procedures. Patients with preop-
erative renal insufficiency were routinely given oral acetyl-
cystine before interventions and patients with severe
azotemia were hydrated preprocedure and postprocedure
with sodium bicarbonate solution. Selective angiography
was performed with the patient under local anesthesia
through a contralateral, retrograde, or ipsilateral antegrade
common femoral artery approach using 5F or 6F sheaths.
No popliteal punctures were used for vascular access. Le-
sions were crossed with platinum-tipped (0.018, 0.014) or
hydrophilic wires (0.035, 0.018, 0.014) and balloon angio-
plasty was performed under systemic anticoagulation. Sub-
intimal angioplasty was not intentionally used to traverse
occluded lesions. Balloon catheter diameter was chosen to
match the nondiseased artery adjacent to the lesion. A
selective approach to the use of Nitinol self-expanding
stents was used for flow-limiting dissections or when angio-
plasty alone did not produce a satisfactory result (residual
stenosis of 30% or a flow-limiting dissection).
Postprocedure, all patients were given a loading dose of
clopidogrel (300 mg) and maintained on 75 mg per day for
6 to 12 weeks. Patients also received 325 mg of aspirin on
the day of the procedure, which was continued indefinitely.
Sheaths were removed under manual compression and
closure devices were rarely used.
Postprocedure follow-up. Patients were routinely
evaluated at 6 weeks in the outpatient setting with clinical
examination and lower extremity noninvasive studies,
which included both ABI and pulse volume recordings mPVR), and then at 6-month intervals thereafter. Patients
ith noncompressible vessels were most commonly fol-
owedwith PVRs. Patency was determined according to the
utherford guidelines11 and patients who were found to
ave absent distal pulses, a return of symptoms, or a change
n ABI/PVR were imaged further. Follow-up also involved
review of all outpatient clinic visits and hospital admis-
ions documented in our system-wide electronic medical
ecords.
Definitions and endpoints. PTA/stent was consid-
red angiographically successful when all technically acces-
ible lesions were treated with a less than 20% residual
tenosis. Hemodynamic success was defined as an ABI
ncrease of at least 0.10 or improvement in plethysmo-
raphic tracing by at least 5 mm for patients with noncom-
ressible vessels. Clinical success was defined as an improve-
ent of at least one clinical category with demonstrable
emodynamic success for patients in category 4. Patients
ith tissue loss (categories 5 and 6) required an improve-
ent to at least claudication and healing of their ulcers with
onfirmed improved hemodynamics as defined by pub-
ished reporting standards.11 A failure of primary patency
ncluded a return of symptoms in the face of worsening
BIs or dampened PVRs due to recurrent infrainguinal
isease. Assisted patency was achieved through a secondary
TA/stent regardless of whether the recurrent lesion was a
tenosis, occlusion, or a new lesion in the same anatomic
egment. Patients requiring surgical bypass were not in-
luded in the assisted patency calculations. Limb salvage
ncluded all major amputations (below and above knee),
hereas any amputation at or distal to the trans-metatarsal
evel was not considered a failure of limb salvage. Survival
ata were obtained from medical records and the Social
ecurity Database.
Statistical analysis. Actuarial patency and survival anal-
sis was performed using the Kaplan-Meier life tables with
antel-Cox log-rank univariate analysis to identify predictors
f negative outcomes (presented as percentage  SE). Rela-
ive risk and confidence intervals (CIs) were then determined
sing a multivariate Cox proportional hazards model for data
ith variable follow-up. All variables with a P value .10 on
nivariate analysis were initially included in the multivariate
odel. A P value of  .05 was considered significant for all
tatistical analysis.
ESULTS
During the study period, 407 patients underwent
TA/stent on 447 limbs. The indication for PTA/stent
as rest pain (Rutherford classification IV) in 131 limbs
29%) and tissue loss (Rutherford classification V-VI) in
16 limbs (71%). Demographic and clinical factors are
ummarized in Table I with 66% of patients having diabetes
nd 13% requiring dialysis. One hundred sixty-nine patients
39%) underwent multilevel treatment, 72 patients (16%)
ad PTA/stent limited to the crural vessels, and the re-
aining 206 patients (46%) had treatment limited to the
emoropopliteal segment. Lesion characteristics and treat-
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April 20111022 Conrad et alComplications. The overall 30-day mortality was 34
(8%); however, the majority of early deaths were attribut-
able to progression of concurrent comorbidities such as
cardiac and pulmonary disease rather than complications of
the PTA/stent procedures. There were 18 patients (4%)
who developed large groin hematomas/retroperitoneal
bleeds requiring blood transfusion and 9 patients (2%) were
diagnosed with new-onset heparin-induced thrombocyto-
penia. Contrast nephropathy occurred in 8 patients (2%),
but only 1 of these required temporary dialysis. Cardiac
events including congestive heart failure and myocardial
infarction occurred in 10 patients (2%) and 2 patients (1%)
developed compartment syndrome after revascularization.
Follow-up. Mean follow-up was 28 months (range,
0-83 months). The actuarial cumulative primary patency at 5
years was 31%  4% (Fig 1) and the assisted patency was
Table I. Demographic and clinical data of 409 patients
undergoing PTA/stent for chronic critical limb ischemia
Variable (n  409 patients) Number (%)
Average age 72 years  12 years
Male gender 250 (61)
Hypertension 376 (92)
Diabetes 270 (66)
Heart disease 258 (63)
Renal insufficiency (Cr 1.5) 155 (38)
Dialysis dependence 53 (13)
Current smoker 74 (18)
Hyperlipidemia 303 (74)
Congestive heart failure 115 (28)
Anti-lipid agent 254 (62)
Beta-blocker 323 (79)
Warfarin 139 (31)
PTA/stent, Percutaneous transluminal angioplasty with or without stenting.
Table II. Lesion characteristics and procedural details of
447 infrainguinal PTA/stent for chronic critical limb
ischemia
Variable (n  447 limbs) Number (%)
TASC I (n  423)
TASC A 48 (11)
TASC B 115 (27)
TASC C 192 (45)
TASC D 68 (17)
TASC II (n  256)
TASC A 30 (12)
TASC B 177 (69)
TASC C 37 (14)
TASC D 12 (5)
Stent placed 116 (26)
Only crural vessel 73 (16)
1 vessel run-off 241 (54)
Peroneal run-off 116 (26)
Multiple levels 170 (38)
Occlusion 166 (37)
PTA/stent, Percutaneous transluminal angioplasty with or without stenting;
TASC, TransAtlantic Inter-Societal Consensus.75% 4% (Fig 2). Negative predictors of primary patency by multivariate analysis included: diabetes (P .0005; coefficient
.7 [1.6-4.8]), 1 vessel run-off (P  .02; coefficient 1.5
1.1-2.0]), and warfarin use (P  .001; coefficient 1.7 [1.3-
.3]). There were no negative predictors of assisted patency
n multivariate analysis.
There were a total of 197 failures (44%) of primary
atency in the study population (n  447) of which 131
66%) were managed with repeat PTA, 22 (12%) under-
ent bypass grafting, 24 (12%) required primary amputa-
ion for infection or lack of a distal target for revasculariza-
ion, and 20 (10%) were observed. Forty-three of the 131
epeat PTA/stents failed with 22 patients progressing to
urgical bypass and 12 undergoing amputation. There were
total of 44 bypasses performed after PTA/stent failure
uring the study period with 30 (68%) remaining patent
nd 14 (32%) failing with eventual amputation (Fig 3).
here were 79 patients (18%) who underwent planned
inor (transmetatarsal amputation or toe) amputation and
4 of 79 (18%) of these did not heal with the initial
TA/stent.
The 5-year limb salvage rate was 74%  4% (Fig 4).
ignificant predictors of limb loss on multivariate analysis
ncluded: female gender (P  .02; coefficient 2.0 [1.1-
.7]), dialysis dependence (P  .006; coefficient 2.5 [1.3-
.8]), and 1 vessel run-off (P  .04; coefficient 1.8
1.0-3.2]). There were 316 limbs (71%) treated for non-
ealing ulcers, and 180 ulcers (57%) healed after the pri-
ig 1. Actuarial primary patency for patients undergoing percu-
aneous transluminal angioplasty with or without stenting (PTA/
tent) for chronic critical limb ischemia.
0 1 2 3 4 5
ercentage of primary
patency 96.9 64.1 54.7 43.5 36.1 31.5
umber at risk 447 207 117 67 35 13
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Volume 53, Number 4 Conrad et al 1023underwent planned minor amputations around the time of
their PTA/stent. There were 136 ulcers (43%) that did not
heal with 63 patients (20%) progressing to major amputa-
tion, 34 patients died before the ulcer could heal, and 39
patients were unhealed at last follow-up.
The 5-year actuarial survival was 39%  3% (Fig 5).
Factors predictive of mortality on multivariate analysis in-
cluded: dialysis dependence (P  .0003; coefficient 2.3
[1.5-3.5]), diabetes (P  .04; coefficient 1.5 [0.5-2.1]),
Fig 2. Actuarial assisted patency for patients undergoing percu-
taneous transluminal angioplasty with or without stenting (PTA/
stent) for chronic critical limb ischemia.
0 1 2 3 4 5
Percentage of
secondary patency 99.8 95.1 89 85.1 78.5 75.3
Number at risk 447 273 164 105 57 25
SE .2 1.1 2.0 2.4 3.5 4.0
Fig 3. Fate of failed percutaneous transluminal angioplasty with
or without stenting (PTA/stent).and 1 vessel run-off (P  .04; coefficient 1.6 [1.2-2.1]). sISCUSSION
This study represents one of the largest single-center
xperiences with endovascular treatment of patients with
LI and infrainguinal arterial disease. In addition, the
ean follow-up of 28 months is more than double that of
ther recent single-center reports.4,7,10 These data confirm
hat PTA/stents can be performed with low morbidity and
ortality in this high-risk population in which two-thirds
f the patients were diabetic and 40% had renal insuffi-
iency. Although the 5-year actuarial primary patency was
ow (31%), the limb salvage rate of 75% is comparable to
hat of surgical bypass.14
One of the most difficult and controversial aspects of
valuating the efficacy or durability of endovascular proce-
ures in the infrainguinal arterial segment is the determi-
ation of primary patency. This outcome is strictly defined
ith regard to evaluation of infrainguinal bypass grafts by
he Rutherford reporting standards document, which can
e reliably followed with duplex ultrasound.11 However,
he best method of surveillance of native arterial segments
reated with PTA/stent remains controversial. The gold
tandard remains angiography, but such invasive testing at
outine intervals is not practical and exposes patients to an
dditional set of risks from contrast dye and access site
omplications. In a recent Society for Vascular Surgery
ocument addressing performance goals for trials of PTA/
ig 4. Actuarial limb salvage for patients undergoing percutane-
us transluminal angioplasty with or without stenting (PTA/stent)
or chronic critical limb ischemia.
0 1 2 3 4 5
ercentage of
limb salvage 99.6 88.4 85.7 84.1 79.6 74.2
umber at risk 447 281 179 122 70 37
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April 20111024 Conrad et alused to report restenosis of treated arterial segments. How-
ever, this practice has not been reliably accurate in our
practice, as native segments treated with PTA alone are
more difficult to identify on subsequent visits and serial
examinations are often performed by different operators. In
the current study, in the absence of angiographic confirma-
tion, we relied on a combination of change in ABI/PVR,
return of ulcer/symptoms, and duplex findings when avail-
able to most accurately determine the primary patency.
In this series, the 5-year primary patency was 31.5%,
which is almost identical to that of Kudo et al7 (31.4%). The
patency curve also mirrors the results of other institutions
with shorter follow-up. Giles et al4 reported a 2-year pri-
mary patency of 51% (this was 54.7% in the current study),
and a recent meta-analysis of angioplasty for CLI reported
a 3-year patency rate of 48.6%.15 Risk factors reported in
the literature as negative predictors of primary patency after
PTA/stent include hypertension, diabetes, renal failure,
and poor run-off.16-19 In the current series, both diabetes
and poor run-off were predictive of failure of primary
patency on multivariate analysis. In addition, patients on
warfarin were also more likely to fail primary patency, but
this is likely a surrogate marker of more advanced athero-
sclerotic disease. A composite risk of failure of primary
patency was calculated using the multivariate predictors,
and patients with diabetes and poor run-off are 2.68 times
more likely to fail (CI, 1.61-4.46) whereas those with all
three negative predictors (diabetes, poor run-off, and war-
Fig 5. Actuarial survival for patients undergoing percutaneous
transluminal angioplasty with or without stenting (PTA/stent) for
chronic critical limb ischemia.
0 1 2 3 4 5
Percentage of survival 97.1 75.6 64.9 55.2 47 39.9
Number at risk 447 330 230 151 89 42
SE .8 2.1 2.4 2.6 2.8 3.3farin) have a risk coefficient of 4.14 (CI, 2.13-7.58). sThe primary goal of lower extremity revascularization for
LI is salvage of the affected limb. However, in the current
iterature, there is a surprising paucity of information regard-
ng the fate of ulcers after percutaneous revascularization.
iles et al4 reported that 57%of the ulcers in their series healed
fter a PTA/stent and 21% worsened. These results are nearly
dentical to the current series inwhich 57%of the ulcers healed
ver time and 20% requiredmajor amputation (30% of ampu-
ations were performed for infection). These numbers reflect
he complexity of wound care required to heal ulcers in this
atient population. The limb salvage rate of 74% at 60months
n this report is comparable to that of femorotibial bypass with
utogenous vein and certainly better than with prosthetic
onduit.1,2 This has been supported by others who have
ound that despite an inferior primary patency, an infraingui-
al PTA/stent leads to limb salvage rates that range from 80%
o 95% at 1 to 3 years.4,7,20-22
Dialysis dependence was a negative predictor of limb
alvage on multivariate analysis. This is not surprising, as it
eflects both the advanced disease state in these patients and
eneralized systemic morbidity. This finding of dialysis
ependence as a negative predictor is also identified in the
ower extremity bypass literature in which some have sug-
ested that primary amputation is the most appropriate
rimary option in this patient cohort.23 Aulivola et al24
ompared infrapopliteal PTA for limb salvage in patients
ith and without renal failure. They concluded that al-
hough PTA is safe in this population, the poor wound
ealing and limb-salvage rates bring to question its utility in
he infrapopliteal segment. In the current study, patients
ho were female and dependent on dialysis had a compos-
te risk of amputation that is 5 times that of the rest of the
opulation (coefficient 5.07 [2.19-11.75]).
Opponents of the use of PTA/stent of infrainguinal ves-
els as primary therapy for CLI have voiced the concern that
ailure could result in the need for a more distal bypass or
ndovascular injury of target vessels could result in the inabil-
ty to identify a distal target bypass. In the current study, 17
mputations were performed after PTA/stent failure due to
ack of a distal target, but this did not represent a change from
heir preprocedure runoff. Sanford et al25 detailed 66 patients
ho underwent surgical bypass for failed PTA (including 16
24%] tibial vessels) and reported a 12-month primary patency
f 61%. The authors noted that 21% of patients in the PTA
ailure group required a bypass more distal than the original
rtery treated. Joels et al26 performed a blinded, independent
eview of prebypass angiograms after early failure of infrain-
uinal PTA/stent and found that the distal bypass site was
ltered in 28.6% of limbs. These reports support the posture
hat the percutaneous procedures should always be under-
aken with consideration of backup surgical options should
he initial PTA fail.
The major limiting factor of this study remains its retro-
pective nature and continued prospective analysis of PTA/
tenting as first-line therapy for chronic lower extremity isch-
mia is necessary. In addition, the fact that all patients were
reated at a single institution opens the potential for referral/
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Volume 53, Number 4 Conrad et al 1025Finally, although the average follow-up for primary patency is
longer than other single-center series, that of assisted patency
remains short and inevitably, this value would fall with con-
tinued surveillance. However, the high mortality rate in this
patient population over the study period suggests that many
patients will likely bemanaged solely with percutaneous inter-
ventions, as they succumb to other comorbidities.
CONCLUSION
Although primary patency is low, excellent 5-year limb
salvage rates can be achieved in patients with CLI through
secondary interventions. These data, and the 12% annual
death rate, validate PTA/stent as first-line therapy in pa-
tients with CLI.
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